Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Assets (2019 - 2025)

Historic Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $260.7 million.

  • Allogene Therapeutics' Current Assets fell 1435.41% to $260.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.7 million, marking a year-over-year decrease of 1435.41%. This contributed to the annual value of $303.4 million for FY2024, which is 3391.94% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Current Assets is $260.7 million, which was down 1435.41% from $282.7 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Current Assets high stood at $716.1 million for Q1 2021, and its period low was $260.7 million during Q3 2025.
  • For the 5-year period, Allogene Therapeutics' Current Assets averaged around $451.8 million, with its median value being $471.3 million (2021).
  • Over the last 5 years, Allogene Therapeutics' Current Assets had its largest YoY gain of 4195.9% in 2021, and its largest YoY loss of 4423.07% in 2021.
  • Allogene Therapeutics' Current Assets (Quarter) stood at $471.3 million in 2021, then rose by 12.2% to $528.8 million in 2022, then fell by 13.18% to $459.1 million in 2023, then tumbled by 33.92% to $303.4 million in 2024, then fell by 14.06% to $260.7 million in 2025.
  • Its Current Assets was $260.7 million in Q3 2025, compared to $282.7 million in Q2 2025 and $291.6 million in Q1 2025.